Alexis Yan, an analyst from Morgan Stanley, maintained the Buy rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H. The associated price target was raised to HK$86.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alexis Yan’s rating is based on Jiangsu Hengrui Pharmaceuticals’ strategic out-licensing agreement with Braveheart Bio, which grants the latter ex-Greater China rights to the myosin inhibitor HRS-1893. This deal includes a significant upfront payment and potential milestone payments, indicating strong commercial prospects. The Phase 1 data for HRS-1893 showed promising results in reducing obstructive symptoms with a favorable safety profile, which enhances its competitive positioning in the global market.
Furthermore, HRS-1893’s ongoing Phase 3 trial in China for obstructive hypertrophic cardiomyopathy (oHCM) is progressing rapidly, with a large patient enrollment target. Its shorter half-life compared to competitors may allow for more flexible dosing and potentially better safety outcomes. These factors collectively contribute to a positive outlook for Hengrui’s stock, justifying the Buy rating.